Rhumbline Advisers Aptinyx Inc. Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$2.39 - $3.5 $83,640 - $122,486	-34,996 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$2.86 - $4.33 $2,359 - $3,572	825 Added 2.41%	34,996 $105,000
Q4 2020 Feb 10, 2021	BUY	$2.93 - $4.3 $30,425 - $44,651	10,384 Added 43.65%	34,171 $118,000
Q3 2020 Nov 12, 2020	SELL	$3.05 - $4.99 $15,936 - $26,072	-5,225 Reduced 18.01%	23,787 $80,000
Q2 2020 Aug 13, 2020	BUY	$1.99 - $4.4 $57,733 - $127,652	29,012 New	29,012 $121,000
Q2 2019 Aug 14, 2019	SELL	$2.95 - $4.38 $49,026 - $72,791	-16,619 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$3.99 - $19.33 $1,296 - $6,282	-325 Reduced 1.92%	16,619 $67,000
Q4 2018 Jan 31, 2019	BUY	$16.15 - $28.93 $113,582 - $203,464	7,033 Added 70.96%	16,944 $280,000
Q3 2018 Nov 07, 2018	BUY	$20.21 - $31.85 $200,301 - $315,665	9,911 New	9,911 $287,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.